CG
PDLI

Clinton Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Clinton Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-203,669
Closed -$640K – 1175
2016
Q2 		$640K Buy
+203,669
New +$679K 0.03% 594
2016
Q1 		– Sell
-338,293
Closed -$1.2M – 1096
2015
Q4 		$1.2M Buy
338,293
+155,051
+85% +$649K 0.1% 323
2015
Q3 		$922K Buy
183,242
+106,150
+138% +$608K 0.09% 323
2015
Q2 		$496K Buy
77,092
+26,560
+53% +$178K 0.07% 381
2015
Q1 		$355K Buy
50,532
+33,540
+197% +$243K 0.09% 322
2014
Q4 		$131K Sell
16,992
-29,965
-64% -$237K 0.04% 438
2014
Q3 		$351K Buy
+46,957
New +$436K 0.14% 240

Other funds holding PDLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Clinton Group's PDLI Position: Q3 2016 in Review

Clinton Group sold out of PDL BioPharma, Inc. (PDLI) in Q3 2016, closing a stake of 203,669 shares — an estimated $640K sold.

Clinton Group first reported a position in PDLI in Q3 2014 and held it in 7 quarters. The position peaked at $1.2M in Q4 2015. 197 funds tracked by Wall St. Rank hold PDLI as of Q3 2016.

  • Clinton Group reported no remaining PDL BioPharma, Inc. position as of Q3 2016 after selling out during the quarter.
  • Clinton Group sold 203,669 PDL BioPharma, Inc. shares in Q3 2016, an estimated $640K.
  • Clinton Group first reported a position in PDL BioPharma, Inc. in Q3 2014 and held it in 7 quarters.
  • Clinton Group's PDL BioPharma, Inc. position peaked at $1.2M in Q4 2015.
  • 197 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2016.

Based on Clinton Group's 13F filing for Q3 2016, filed 14 Nov 2016.